摘要
目的:评价莫西沙星治疗老年社区获得性肺炎(CAP)的临床功效和毒副作用。方法:回顾性调查我院2010年6月至2012年6月治疗的老年CAP患者196例,莫西沙星治疗组(试验组)98例,头孢哌酮舒巴坦钠治疗组(对照组)98例,对其疗效和副作用进行临床观察。结果:总有效率分别为试验组90.8%,对照组69.6%(P=0.34);痊愈率分别为试验组81.6%,对照组60.2%(P=0.38),试验组细菌清除率为86.5%;对照组细菌清除率为64.0%(P=0.04);不良反应发生率分别为试验组6%,对照组4%(P=0.7)。结论:莫西沙星治疗CAP的疗效好,毒副作用相对较低,值得临床推广使用。
Objective To evaluate the clinical efficacy and toxic side effect of moxifloxacin in the treatment of elderly patients with community acquired pneumonia （CAP）. Methods 196 elderly patients with CAP were reviewed from June 2010 to June 2012 in our hospital, which were randomly divided into 98 cases of moxifloxacin group （test group ） and 98 cases of cefoperazone sulbactam group （control group ） , to evaluate its clinical efficacy and toxic side effect. Results The total effective rate was 90.8% in the test group and 69.6% in the control group respectively （P = 0.34） ;The cure rate was 81.6% in the test group and 60.2% in the control group respectively（P = 0.38） ;The bacterial clearance rate was 86.5% in test group and 60.2% in the control group respectively（P = 0.04） ; The incidence of adverse events was 6% in the test group and 4% in the control group respectively （P = 0.7）. Conclusion Moxifloxacin have satisfactory effects in treating CAP, with low toxic side effect, is worthy to recommand its clinical apptycation.
出处
《实用医学杂志》
CAS
北大核心
2013年第16期2610-2612,共3页
The Journal of Practical Medicine
基金
郑州大学呼吸科基金资助(编号:20110 20002)
